The Patent Trial and Appeal Board (PTAB) handed down a series of Final Written Decisions that gave our client, FlatWing Pharmaceuticals, a string of victories. FlatWing had filed four petitions for inter partes review challenging multiple Anacor Pharmaceuticals patents. In each instance, PTAB returned a decision that invalidated the patent-in-suit. In sum, our team demonstrated that 39 separate claims found in four different patents were “unpatentable as obvious over the cited prior art.”